TABLE 2.
Serologic data and biopsy results.
| Variables | Cohort | Data (n) |
|---|---|---|
| DSA characteristics | ||
| DSA-positive, n (%) | 75 (100) | 75 |
| HLA class I DSA | 45 (63.4) | 71 |
| HLA class II DSA | 60 (84.5) | 71 |
| HLA class I plus II DSA | 34 (47.9) | 71 |
| DSA-MFI a >10,000 | 31 (42.5) | 73 |
| Morphologic biopsy results | ||
| ABMR phenotypes, n (%) | ||
| Active ABMR | 15 (20) | 75 |
| Chronic active ABMR | 47 (62.7) | 75 |
| Chronic (inactive) ABMR | 13 (17.3) | 75 |
| Peritubular capillary C4d deposition | 30 (40.0) | 75 |
| Single lesion scores, median (IQR) | ||
| Capillary C4d (c4d) | 0 (0 to 2) | 75 |
| Glomerulitis (g) | 2 (1 to 2) | 72 |
| Peritubular capillaritis | 1 (0 to 2) | 75 |
| Intimal arteritis (v) | 0 (0 to 0) | 62 |
| Glomerular double contours (cg) | 1 (0 to 2) | 72 |
| Interstitial fibrosis (ci) | 2 (1 to 3) | 75 |
| Tubular atrophy (ct) | 1 (1 to 2) | 75 |
| Vascular fibrous intimal thickening (cv) | 1 (1 to 2) | 62 |
| Sum scores, median (IQR) | ||
| AI (g+ptc+v+C4d) | 4 (2 to 5) | 61 |
| AI3comp (g+ptc+C4d) | 4 (3 to 5) | 72 |
| CI (ci+ct+cv+[cgx2]) | 7 (4 to 10) | 61 |
| CI3comp (ci+ct+[cgx2]) | 6 (3 to 8) | 72 |
| Banff borderline lesion, n (%) | 4 (5.3) | 75 |
| Mixed rejection, n (%) | 2 (2.7) | 75 |
| BK virus nephropathy, n (%) | 1 (1.3) | 75 |
| Glomerulonephritis, n (%) b | 3 (4.0) | 75 |
| Molecular biopsy results (MMDx) | ||
| Rejection-associated scores, median (IQR) | ||
| ABMRProb c | 0.54 (0.32 to 0.73) | 75 |
| TCMR | 0.03 (0.02 to 0.05) | 75 |
| “all Rejection” score | 0.67 (0.44 to 0.82) | 75 |
| Injury-associated scores, median (IQR) | ||
| IRRAT | 0.19 (−0.13 to 0.54) | 75 |
| ciprob | 0.58 (0.30 to 0.75) | 75 |
| Most probable archetype, n (%) | ||
| No rejection | 15 (20) | 75 |
| TCMR | 1 (1.3) | 75 |
| Early-stage ABMR | 20 (26.7) | 75 |
| Fully-developed ABMR | 31 (41.3) | 75 |
| Late-stage ABMR | 8 (10.7) | 75 |
ABMR, antibody-mediated rejection; AI, activity index; CI, chronicity index; ciprob, molecular classifier reflecting the probability of histologic ci lesion score >1; DSA, donor-specific antibody; IQR, interquartile range; IRRAT, transcript set associated with injury-repair response; MFI, mean fluorescence intensity; TCMR, T cell-mediated rejection.
a
MFI of the immunodominant DSA.
b
Cases of glomerulonephritis included two cases of IgA nephropathy and one case of unspecified immune complex-mediated glomerulonephritis.
c
Sixty-three recipients (84%) had an ABMRProb score >0.2.